The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26916048.
- Also identified by DOI 10.1016/j.eururo.2016.02.032.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
One of the most effective ways to reduce overtreatment of prostate cancer is to limit its detection in men with low-risk disease. Although many data are currently missing, we foresee a future with reduced prostate-specific antigen (PSA) testing in men selected through baseline PSA values or genetic predisposition. Then selective biopsy using multiparametric magnetic resonance imaging and longitudinal biomarkers will play a role.
Medical subject headings
- Prostate-Specific Antigen
- Prostatic Neoplasms
- Unnecessary Procedures